Skip to main content
logo
McKesson Corporation (BMV:MCK)
Mexico flag Mexico · Delayed Price · Currency is MXN
13,341
0.00 (0.00%)
Last updated: Aug 6, 2025

Revenue by Product

Fiscal year is April - March.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 20212017 - 2020
Period Ending
Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 2017 - 2020
Other
11.00M
Log In
Log In
Log In
Log In
Upgrade
Medical Surgical Solutions
11.39B
Log In
Log In
Log In
Log In
Upgrade
Medical Surgical Solutions Growth
1.00%
Log In
Log In
Log In
Log In
Upgrade
US Pharmaceutical
327.72B
Log In
Log In
Log In
Log In
Upgrade
US Pharmaceutical Growth
22.12%
Log In
Log In
Log In
Log In
Upgrade
Prescription Technology Solutions
5.22B
Log In
Log In
Log In
Log In
Upgrade
Prescription Technology Solutions Growth
13.49%
Log In
Log In
Log In
Log In
Upgrade
International
14.72B
Log In
Log In
Log In
Log In
Upgrade
International Growth
2.89%
Log In
Log In
Log In
Log In
Upgrade
Other
11.00M
Log In
Log In
Log In
Log In
Upgrade
Other
11.00M
Log In
Log In
Log In
Log In
Upgrade

Capex by Product

Fiscal year is April - March.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 20212017 - 2020
Period Ending
Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 2017 - 2020
Other
15.00M
Log In
Log In
Log In
Log In
Upgrade
Other Growth
-
Log In
Log In
Log In
Log In
Upgrade
Medical Surgical Solutions Capital Expenditures
163.00M
Log In
Log In
Log In
Log In
Upgrade
Medical Surgical Solutions Capital Expenditures Growth
-
Log In
Log In
Log In
Log In
Upgrade
Other
15.00M
Log In
Log In
Log In
Log In
Upgrade
Other Growth
-
Log In
Log In
Log In
Log In
Upgrade
US Pharmaceutical Capital Expenditures
241.00M
Log In
Log In
Log In
Log In
Upgrade
US Pharmaceutical Capital Expenditures Growth
-
Log In
Log In
Log In
Log In
Upgrade
Prescription Technology Solutions Capital Expenditures
11.00M
Log In
Log In
Log In
Log In
Upgrade
Prescription Technology Solutions Capital Expenditures Growth
-
Log In
Log In
Log In
Log In
Upgrade
International Capital Expenditures
107.00M
Log In
Log In
Log In
Log In
Upgrade
International Capital Expenditures Growth
-
Log In
Log In
Log In
Log In
Upgrade
Other
15.00M
Log In
Log In
Log In
Log In
Upgrade
Other Growth
-
Log In
Log In
Log In
Log In
Upgrade

EBIT by Product

Fiscal year is April - March.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 20212017 - 2020
Period Ending
Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 2017 - 2020
Other
-522.00M
Log In
Log In
Log In
Log In
Upgrade
Other Growth
343.17%
Log In
Log In
Log In
Log In
Upgrade
Other
-522.00M
Log In
Log In
Log In
Log In
Upgrade
Other Growth
343.17%
Log In
Log In
Log In
Log In
Upgrade
Medical Surgical Solutions Operating Profit
773.00M
Log In
Log In
Log In
Log In
Upgrade
Medical Surgical Solutions Operating Profit Growth
-11.72%
Log In
Log In
Log In
Log In
Upgrade
Other
-522.00M
Log In
Log In
Log In
Log In
Upgrade
Other Growth
343.17%
Log In
Log In
Log In
Log In
Upgrade
US Pharmaceutical Operating Profit
4.00B
Log In
Log In
Log In
Log In
Upgrade
US Pharmaceutical Operating Profit Growth
44.09%
Log In
Log In
Log In
Log In
Upgrade
Prescription Technology Solutions Operating Profit
875.00M
Log In
Log In
Log In
Log In
Upgrade
Prescription Technology Solutions Operating Profit Growth
14.62%
Log In
Log In
Log In
Log In
Upgrade
International Operating Profit
-213.00M
Log In
Log In
Log In
Log In
Upgrade
International Operating Profit Growth
-159.94%
Log In
Log In
Log In
Log In
Upgrade